

Evaluation of the Role of Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangio Pancreatography (ERCP) Pancreatitis

Thesis

*Submitted for Partial Fulfillment of MD Degree
in Tropical Medicine*

By

Ahmad Hussein Abdelhamid Hassan

M.B., B.Ch. M.Sc.

Faculty of Medicine - Ain Shams University

Under Supervision of

Prof. Dr. Moubarak Mohammed Hussein

Professor of Tropical Medicine

Faculty of Medicine - Ain Shams University

Prof. Dr. Mohammed Reda Elwakil

Professor of Tropical Medicine

Faculty of Medicine - Ain Shams University

Prof. Dr. Amany Ahmad Ibrahim

Professor of Tropical Medicine

Faculty of Medicine - Ain Shams University

Prof. Dr. Eman Fathy Barakat

Professor of Tropical Medicine

Faculty of Medicine - Ain Shams University

Dr. Hossam Eldin Mohammed Salem

Lecturer of Tropical Medicine

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2015



Acknowledgment

*First and foremost, thanks and grateful to **ALLAH** for giving me the power and strength to carry out this work.*

*My profound thanks and deep appreciation to **Prof. Dr. Moubarak Mohammed Hussein**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University for his generous help, valuable remarks and continuous guidance. It has been a great honor to work under his supervision.*

*I am deeply indebted to **Prof. Dr. Mohammed Reda Elwakil**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University for his continuous inexhaustible help and direction that extended throughout this work. He gave me the confidence and encouragement to complete this work.*

*I would like also to express my deep and special thanks to **Prof. Dr. Amany Ahmad Ibrahim**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University for her generous guidance, advice and patience throughout all the stages of this work.*

*Many thanks to **Prof. Dr. Eman Fathy Barakat**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University for her caring and continuous support.*

*Many thanks to **Dr. Hossam Eldin Mohammed Salem**, Lecturer of Tropical Medicine, Faculty of Medicine, Ain Shams University for his help and support.*

*I am deeply grateful to **my mother and my sister** who directed, supported and encouraged me during the preparation of this work.*



Contents

Title	Page
List of Abbreviations	I
List of Tables	II
List of Figures	IV
Introduction.....	1
Aim of the Work.....	4
Review of Literature.....	
- Chapter (1): Anatomy of the Biliary System.....	6
- Chapter (2): Complications of ERCP.....	36
- Chapter (3): Allopurinol	71
Patients and Methods	78
Results.....	89
Discussion	111
Summary	125
Conclusion	128
Recommendations	129
References.....	130
Arabic Summary	--

List of Abbreviations

Abb.	Mean
ALT	Alanine transaminase.
AST	Aspartate transaminase.
BUN	Blood urea nitrogen.
CBD	Common bile duct.
CLD	Chronic liver disease
COPD	Chronic obstructive airway disease.
EPBD	Endoscopic papillary balloon dilation.
ERCP	Endoscopic retrograde cholangio-pancreatography.
ES	Endoscopic sphincterotomy.
EUS	Endoscopic ultrasound.
GA	General Anesthesia.
GGT	Gamma glutamyl transferase.
i.v.	Intra venous
IHBRD	Intra hepatic biliary radicals dilatation.
MRCP	Magnetic resonance cholangio-pancreatography.
n	Number
OJ	Obstructive jaundice.
PEP	Post ERCP pancreatitis.
PTC	Percutaneous transhepatic cholangiography.
SD	Standard deviation.
SOD	Sphincter of Oddi dysfunction.
WBCs	White blood cells.

List of Tables

Page no.	Title	Table no.
Table (1)	Definitions and grading system for the major complications of ERCP and therapy.	38
Table (2)	Summary of the overall complications and severity in a study done in Egypt in Ain Shams University Hospitals.	41
Table (3)	Demographic data of the studied groups.	90
Table (4)	Comparison between the studied groups regarding the clinical picture before ERCP.	90
Table (5)	Comparison between the studied groups regarding comorbidities.	91
Table (6)	Comparison between the studied groups regarding imaging findings before ERCP.	91
Table (7)	Comparison between the studied groups regarding the final diagnosis according to ERCP findings.	92
Table (8)	Comparison between the studied groups regarding ERCP procedures.	93
Table (9)	Comparison between the studied groups regarding White blood cells count.	94
Table (10)	Comparison between the studied groups regarding platelets count (x10 ³ /mL).	95
Table (11)	Comparison between the studied groups regarding serum blood urea nitrogen (BUN) level.	96
Table (12)	Comparison between the studied groups regarding serum creatinine level.	97
Table (13)	Comparison between the studied groups regarding serum potassium level.	98
Table (14)	Comparison between the studied groups regarding serum ALT level.	99
Table (15)	Comparison between the studied groups regarding serum AST level.	100

Page no.	Title	Table no.
Table (16)	Comparison between the studied groups regarding serum alkaline phosphatase level.	101
Table (17)	Comparison between the studied groups regarding serum Gamma glutamyl transferase (GGT) level .	102
Table (18)	Comparison between the studied groups regarding serum bilirubin level.	103
Table (19)	Comparison between the studied groups regarding serum amylase level.	104
Table (20)	Comparison between the studied groups regarding serum lipase level.	105
Table (21)	Comparison between the studied groups regarding post ERCP complications.	106
Table (22)	Comparison between cases with and without pancreatitis in the control group.	107
Table (23)	Comparison between the studied groups regarding ERCP procedure.	109

List of Figures

Figure no.	Title	Page no.
Figure (1)	Anatomy of the gall bladder and bile ducts	7
Figure (2)	Diagrammatic view of the pancreas showing the main and accessory ducts as well as major and minor duodenal papillae.	16
Figure (3)	Papillotome and guidewire cannulation.	29
Figure (4)	Guidewire in pancreatic duct to aid biliary cannulation.	29
Figure (5)	Procedure of ERCP.	86
Figure (6)	Some ERCP instruments.	87
Figure (7)	Mean WBC among the studied groups.	94
Figure (8)	Mean platelets among groups.	95
Figure (9)	Mean serum BUN among groups.	96
Figure (10)	Mean serum creatinine among groups.	97
Figure (11)	Mean serum potassium among groups.	98
Figure (12)	Median serum ALT among groups.	99
Figure (13)	Median serum AST among groups.	100
Figure (14)	Median alkaline phosphatase among groups.	101
Figure (15)	Median serum GGT among groups.	102
Figure (16)	Median serum bilirubin among groups.	103
Figure (17)	Median serum amylase among groups.	104
Figure (18)	Median serum lipase among groups.	105
Figure (19)	Complications among groups.	106
Figure (20)	Comparison between cases with and without pancreatitis in control regarding age.	108

Figure no.	Title	Page no.
Figure (21)	Comparison between cases with and without pancreatitis in control regarding precut needle sphincterotomy.	108
Figure (22)	Comparison between cases with and without pancreatitis in control regarding injected dye.	110
Figure (23)	Comparison between cases with and without pancreatitis in control regarding unintended pancreatic duct cannulation..	110

Introduction

Since its introduction in 1968, endoscopic retrograde cholangio-pancreatography (ERCP) has become a commonly performed endoscopic procedure. The diagnostic and therapeutic utility of ERCP has been demonstrated for a variety of disorders (*Mallery et al., 2003*). ERCP is a technically demanding endoscopic procedure that varies from a simple diagnostic to a highly complex therapeutic procedure. It has variable degrees of technical success and many complications, such as pancreatitis, hemorrhage, perforation and infection (*Mallery et al., 2003*).

Pancreatitis is the most common ERCP complication (*Freeman et al., 2001*), with an incidence ranging from 1.8% to 7.2% in most prospective series (*Williams et al., 2007*). However, the reported incidence can go up to 30%, depending on the criteria used in diagnosis of pancreatitis, the type and the duration of patient follow-up (*Freeman and Guda, 2004*). More commonly, hyperamylasemia occurs up to 30% of the patients undergoing ERCP (*LaFerla et al., 1986*). An early step in the pathogenesis of acute pancreatitis is capillary endothelial injury manifested by an increase in capillary

permeability (*Sanfey and Cameron, 1984*). Subsequent research has suggested that this capillary injury might be mediated by oxygen-derived free radicals (*Schoenberg et al., 1994*).

Xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine, which generates an oxygen-derived free radical (*Masci et al., 2003*). Xanthine dehydrogenase is converted to xanthine oxidase by the proteolytic cleavage of a peptide fragment. These findings have prompted attempts for prevention of pancreatitis by treatment with free radical scavengers (e.g. superoxide dismutase, dimethyl sulfoxide or catalase), protease inhibitors (e.g. gabexate) or xanthine oxidase inhibitors (e.g. allopurinol) (*Masci et al., 2003*).

Some attempts have been made to find pharmacologic agent that could be used to reduce the incidence and severity of post-ERCP Pancreatitis (PEP). An ideal agent should be highly effective in reducing PEP, safe for the patient, well tolerated, relatively affordable and does not require a prolonged administration time (*Cooper and Slivka, 2007*).

The efficacy of oral allopurinol to reduce PEP has been investigated in an in vivo animal model (*Marks et al., 1998*).

Pretreatment was not only associated with a significant (six folds) reduction in the incidence of pancreatitis, but when pancreatitis did occur it was less severe. Other animal models using pretreatment with allopurinol have demonstrated a significant reduction in progression of the histological pancreatic injury and in the severity of experimental pancreatitis in dog and rat models (*Isik et al., 2006; Shabanov et al., 2006; and Comert et al., 2007*).

These findings in animal research supported the need for human studies on the utility of allopurinol pretreatment to reduce the incidence of hyperamylasemia and PEP. One randomized clinical trial has reported positive clinical results (*Katsinelos et al., 2005*), whereas others have reported negative outcomes (*Romagnuolo et al., 2008*).

Allopurinol is also an inexpensive generic drug with an excellent safety record and is not included among list of drugs inducing pancreatitis (*Badalov et al., 2007*).

Aim of the Work

The aim of this study is to evaluate prospectively the use of allopurinol in the prevention of post – ERCP pancreatitis in patients undergoing ERCP.

Patients and Methods

A prospective study will be conducted on 100 patients of both sexes who will undergo ERCP procedure in Ain Shams University Hospitals will be enrolled into the study, their age ranges from 20-70 years old. They will be randomized and divided into **2 groups**:

Group 1: 50 patients who will receive allopurinol tablets before the ERCP procedure (**study group**).

Group 2: 50 patients will undergo ERCP without allopurinol prophylaxis (**control group**).

All the patients will sign a written informed consent

Study design:

A- Sample size:

EPI.Info program was used for sample size calculation guided by

1. Power of the test = 80%
2. Confidence level = 95%
3. Alfa error = 5%
4. Expected response rate = 60%

The minimal total sample size that achieve significance will be 100 cases divided into 2 equal groups:

1. 1st group (50 cases): will receive allopurinol drug prior to ERCP.
2. 2nd group (50cases): will not receive the drug.

B- Type of the study:

Randomized controlled clinical trial (RCCT).

C- Sampling plan:

Cases will be allocated by *Systematic Random Sample* according to their number into:

1. Odd numbers: 50 cases of the first group.
2. Even number: 50 cases of the second group.

Inclusion criteria:

All patients candidate for ERCP will be included in this study for ERCP:

1. Patients with calcular obstructive jaundice.
2. Patients with malignant or benign obstructive jaundice.
3. Patients with any other indications for ERCP.

Exclusion criteria:

1. Patients refusing to undergo the procedure or signing the informed consent.

2. Patients with clinically evident acute pancreatitis or hyperamylesemia (>150 IU/L) before the procedure.
3. Patients had undergone previous endoscopic or surgical sphincterotomy.
4. Current or recent use of allopurinol (within the last 48 hours).
5. Patients who are allergic or hypersensitive to allopurinol or hydro soluble contrast solutions.
6. Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid.
7. Patients receiving NSAIDS within a week prior to assessment.
8. Severe co-morbid conditions (eg. cardiovascular, renal failure or patients with decompensated cirrhosis).
9. Female patients with a known or suspected pregnancy lactating (*Martinez et al., 2009*).

End points: Patients having any of the complications such as hemorrhage, perforation, etc, will end up their study.

Drug safety: The following adverse effects might happen during the procedure due to use of allopurinol such as diarrhea;